Richard LeBlanc

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

Medicine, Oncology, Pharmacotherapy +14

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Paul G. Richardson, Robert Schlossman, Edie Weller et al. · Blood · 2002 · 804 citations · Full text

Medicine, Immunology, Pharmacology +12

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 788 citations

Medicine, Pharmacology, Pharmacotherapy +15

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki et al. · New England Journal of Medicine · 2018 · 535 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17